UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K


                                 CURRENT REPORT

                     Pursuant to Section 13 or 15(d) of the
                         Securities Exchange Act of 1934

                Date of Report (Date of earliest event reported)
                                  May 22, 2009

                           HEMISPHERX BIOPHARMA, INC.
             (Exact name of registrant as specified in its charter)

                           Delaware 0-27072 52-0845822
               (state or other juris- (Commission (I.R.S. Employer
           diction of incorporation) File Number) (Identification No.)

              1617 JFK Boulevard, Philadelphia, Pennsylvania 19103
               (Address of principal executive offices) (Zip Code)

       Registrant's telephone number, including area code: (215) 988-0080

          ______________________________________________________________
          (Former name or former address, if changed since last report)


Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act
    (17 CFR 230.425)

[ ] Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act
    (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
    Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
    Act (17 CFR 240.13e-4(c))









Section 7 - Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure.

On May 26, 2009, we issued a press release,  in which we announced that the U.S.
Food and Drug  Administration  has advised the Company that it may require up to
1-2 additional weeks to take action beyond the scheduled  Prescription Drug User
Fee  Act  action  date  of  May  26,  2009  on  the  New  Drug  Application  for
Ampligen(R)(Poly I POly C12U), a selective TLR3 modulator, for the management of
Chronic Fatigue Syndrome. The text of this press release is set forth as Exhibit
99.1

In accordance with the general  instructions B.6 of form 8-K, the information in
this  report,  including  Exhibit  99.1,  is  furnished  and shall not be deemed
"filed" for the purposes of section 18 of the  Securities  Exchange Act of 1934,
as amended (the "Exchange  Act"), or otherwise  subject to the liability of that
section,  or incorporated by reference in any filing under the Securities Act of
1933, as amended, or the Exchange Act, except as shall be expressly set forth by
specific references in such filing.

Item 9.01.        Financial Statements and Exhibits.

              (c) Exhibits:

                 99.1          Press Release dated May 26, 2009.








                                   SIGNATURES


Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                            HEMISPHERX BIOPHARMA, INC.


May 26,  2009                 By:         /s/ William A. Carter
                                            ---------------------
                                            William A. Carter M.D.,
                                            Chief Executive Officer








                                                           Exhibit 99.1

Company/Investor Contact:
Dianne Will                                             Mark Collinson
Hemispherx Biopharma, Inc.                              CCG Investor Relations
518-398-6222                                            310-477-9800
ir@hemispherx.net

HEMISPHERX BIOPHARMA ANNOUNCES POSSIBLE BRIEF DELAY IN FDA ACTION ON AMPLIGEN(R)
                              NEW DRUG APPLICATION

Philadelphia,  PA, May 26, 2009 - Hemispherx  Biopharma,  Inc.  (NYSE/AMEX -HEB)
today announced that the U.S. Food and Drug  administration  ("FDA") has advised
the company that it may require up to 1-2 additional weeks to take action beyond
the scheduled  Prescription Drug User Fee Act action date of May 25, 2009 on the
New Drug  Application  for  Ampligen(R)  (Poly I Poly C12U),  a  selective  TLR3
modulator,  for the  management  of  Chronic  Fatigue  Syndrome.  Reason for the
possible delay was attributed by the Agency to certain staff scheduling  changes
which  might  (or  might  not)  delay  the  report.  Accordingly  the  Company's
development  plan for  Ampligen(R)  continues as described in the recently filed
10Q and 10K, as the FDA did not request additional  information from the Company
at this time.

About  Hemispherx  Biopharma  Hemispherx  Biopharma,  Inc. is a specialty pharma
company engaged in the manufacture and clinical development of new drug entities
for  treatment  of  seriously  debilitating  disorders.   Hemispherx's  flagship
products include Alferon N Injection(R) (FDA approved for a category of sexually
transmitted  diseases)  and  the  experimental   therapeutics   Ampligen(R)  and
Oragens(R).  Ampligen(R) and Oragens(R) represent experimental RNA nucleic acids
being developed for globally  important  debilitating  diseases and disorders of
the immune system.  Hemispherx's  platform  technology  includes large and small
agent components for potential  treatment of various  severely  debilitating and
life  threatening  diseases.  Hemispherx  has in  excess  of 50  issued  patents
comprising  its core  intellectual  property  estate and a fully  commercialized
product  (Alferon N  Injection(R)).  The  Company  wholly  owns and  exclusively
operates  a GMP  certified  manufacturing  facility  in the  United  States  for
commercial products. For more information please visit www.hemispherx.net

Information  contained in this news release other than  historical  information,
should be considered  forward-looking and is subject to various risk factors and
uncertainties. For instance, the strategies and operations of Hemispherx involve
risk of competition,  changing market conditions, change in laws and regulations
affecting these industries and numerous other factors  discussed in this release
and in the Company's  filings with the Securities and Exchange  Commission.  Any
specifically referenced investigational drugs and associated technologies of the
Company  (including  Ampligen(R),  Alferon LDO and Oragens) are  experimental in
nature  and as such  are not  designated  safe  and  effective  by a  regulatory
authority for general use and are legally available only through clinical trials
with the referenced  disorders.  The  forward-looking  statements  represent the
Company's  judgment  as of the  date of this  release.  The  Company  disclaims,
however,  any intent or obligation to update these  forward-looking  statements.
Clinical trials for other potential indications of the approved biologic Alferon
N Injection(R) do not imply that the product will ever be specifically  approved
commercially for these other treatment indications; Similarly, the completion of
NDA filing process with Ampligen(R) does not imply that the product will ever be
approved commercially. # # #